American Society of Gene Therapy

Preliminary Program

ASGT 7th Annual Meeting
June 2-6, 2004, Minneapolis, Minnesota
Jointly Sponsored by Baylor College of Medicine, Houston, Texas

Program Schedule
(This program is subject to updates/changes.)

Thursday, June 3

George Stamatoyannopoulos Lecture
Lecture 200
8:00 am – 9:00 am
Chair
Katherine A. High, MD

Speaker
Harriet Robinson, PhD - Multi Protein DNA/MVA Vaccine for HIV/AIDS

Workshop 210
9:15 am – 10:45 am
American Society of Transplantation: The Nexus of Cell Transplantation and Gene Therapy
Co-Chairs
Donald B. Kohn, MD
Daniel R. Salomon, MD
Speakers
Jonathan S. Bromberg, MD, PhD
Edward Baetge, PhD
Michel Sadelain, MD, PhD

Workshop 211
9:15 am – 10:45 am
Cancer: Surrogate Markers and Interval End Points
Chair
Akseli E. Hemminki, MD, PhD
Speakers
Stephen J. Russell, MD, PhD
Long P. Le, PhD
Donald Buchsbaum, PhD
Savio L.C. Woo, PhD
Akseli E. Hemminki, MD, PhD

Workshop 212
9:15 am – 10:45 am
Cardiovascular: Targeted Gene Delivery for Myocardial and Vascular Disease
Co-Chairs
Barry J. Byrne, MD, PhD
Frank J. Giordano, MD
Speakers
Xiao Xiao, PhD
Walter J. Koch, PhD
Andrew H. Baker, PhD
Kenneth H. Warrington, Jr., PhD
Vijay K. Yechoor, MD

Workshop 213
9:15 am – 10:45 am
Genetic Disease: Large Animal Models of Genetic Disease
Chair
Mark Haskins, VMD, PhD
Speakers
Mark Haskins, VMD, PhD
Gustavo D. Aguirre, VMD, PhD
Tim C. Nichols, MD
Patrick Aebischer, MD
Joseph Kornegay, DVM, PhD

Workshop 214
9:15 am – 10:45 am
Immunology of Gene Therapy: Biology of Genetically Modified Antigen- Presenting Cells (APCs)
Chair
Karin Jooss, PhD
Speakers
Isabelle Riviere, PhD
Carl H. June, MD
Paul D. Robbins, PhD
Katie Whartenby, PhD

Workshop 215
9:15 am – 10:45 am
Industrial Liaison: Commercializing Gene Therapy - What Will It Take?
Chair
Stephen M.W. Chang, PhD
Speakers
Douglas J. Jolly, PhD
Philip D. Noguchi, MD
Robert E. Sobol, MD
Samuel Wadsworth, PhD

Workshop 216
9:15 am – 10:45 am
Non-Viral: Development and Application of Non-Viral Vectors
Co-Chairs
Seng H. Cheng, PhD
Lluis M. Mir, DSc
Speakers
Lluis M. Mir, DSc
Carol H. Miao, PhD
Mark J. Cooper, MD
David B. Rozema, PhD
Alain Rolland, PharmD, PhD

Workshop 217
9:15 am – 10:45 am
Respiratory Tract: Stem Cell Plasticity: Use of Bone Marrow-Derived Cells for Lung Diseases
Co-Chairs
Daniel Weiss, MD, PhD
Guoshun Wang, PhD, DVM
Speakers
Daniel Weiss, MD, PhD
Xiaoming Liu, PhD
Luis Ortiz, MD
Guoshun Wang, PhD, DVM
Jeffrey L. Spees, PhD
Susan Reynolds, PhD

Break
10:45 am – 11:00 am

Workshop 220
11:00 am – 12:30 pm
Gene-Based Vaccines: Influence of Vector-Induced Innate Immunity of Gene-Based Vaccines
Chair
Eyal Raz, MD
Speakers
Eyal Raz, MD
Art Krieg, MD
Daniel A. Muruve, MD

Workshop 221
11:00 am – 12:30 pm
Hemopoietic: Harnessing Novel Sources of Stem Cells for Therapy
Chair
Jan Nolta, PhD
Speakers
Peter Quesenberry, MD
Thalia Papayannopoulou, MD
Margaret Goodell, PhD
Fabio Rossi, MD, PhD

Workshop 222
11:00 am – 12:30 pm
International Harmonization of Regulatory Standards
Co-Chairs
Odile Cohen-Haguenauer, MD, PhD
Estuardo Aguilar-Cordova, PhD
Speakers
Lucio Luzzatto, MD, PhD
Odile Cohen-Haguenauer, MD, PhD
Beth Hutchins, PhD
Philip D. Noguchi, MD
Theodore Friedmann, MD

Workshop 223
11:00 am – 12:30 pm
Infectious Disease: Viral Cellular Co-Factors as Targets for Gene Therapy
Chair
Didier Trono, MD
Speakers
Didier Trono, MD
David Strayer, MD, PhD
Mauro Giacca, MD, PhD
Reuben S. Harris, PhD

Workshop 224
11:00 am – 12:30 pm
Musculo-Skeletal: Designing and Planning Clinical Trials for Musculo-Skeletal Diseases
Chair
Jeffrey Chamberlain, PhD
Speakers
Jon Wolff, MD
Alan J. Nixon, BVSc, MS
Haim Burstein, PhD
Jeffrey Chamberlain, PhD

Workshop 225
11:00 am – 12:30 pm
Neural Disorders: The Neuroimmunology of Gene Therapy
Chair
Pedro Lowenstein, MD, PhD
Speakers
Trevor Owens, PhD
John Forsayeth, PhD
Howard J. Federoff, MD, PhD
E. Antonio Chiocca, MD, PhD
Ronald Mandel, PhD

Workshop 226
11:00 am – 12:30 pm
Viral: DNA Vector Targeting
Chair
Stefan Kochanek, MD
Speakers
Michael Hallek, MD
Jeffrey S. Bartlett, PhD
Michael A. Barry, PhD
Joel N. Glasgow, PhD

Meet-the-Investigator 230
12:30 pm – 1:30 pm
Gene Therapy for Cancer: Academic and Industry Implementation
Estuardo Aguilar-Cordova, PhD

Meet-the-Investigator 231
12:30 pm – 1:30 pm
Gene and Cell Therapy for Muscular Disorders
Olivier Danos, PhD

Meet-the-Investigator 232
12:30 pm – 1:30 pm
Title: To be announced
Sir Aaron Klug, OM, FRS

Meet-the-Investigator 233
12:30 pm – 1:30 pm
Increasing the Potency of Cancer Immunotherapeutics and Vaccines: Immunogenicity of Transgene and Anti-Vector Responses
Margaret A. Liu, MD

Meet-the-Investigator 234
12:30 pm – 1:30 pm
Ups & Downs, Ins & Outs of Gene Therapy
Inder Verma, PhD

Simultaneous Oral Abstract Sessions
1:45 pm – 4:15 pm

Oral Abstract Session 240
Vector Integration and Mobilization
Moderators
Kyriacos A. Mitrophanous, PhD
Paula M. Cannon, PhD

Oral Abstract Session 241
AAV Vectors: Genome and Capsid Modifications
Moderators
Robert M. Kotin, PhD
Matthew Weitzman, PhD

Oral Abstract Session 242
Adenovirus Biology and Disease Applications
Moderators
Joseph T. Bruder, PhD
Michael J. Imperiale, PhD

Oral Abstract Session 243
Other DNA Viruses
Moderators
William J. Bowers, PhD
David L. Bartlett, MD

Oral Abstract Session 244
Inborn Errors of Metabolism: Hemophilia and Other Disorders
Moderators
Roland W. Herzog, PhD
Brendan Lee, MD, PhD

Oral Abstract Session 245
Neuro Gene Therapy I: New Approaches for Dominant, Recessive, Degenerative and Autoimmune
Moderators
Howard J. Federoff, MD, PhD
Pedro Lowenstein, MD, PhD

Oral Abstract Session 246
Novel Cancer Targeted Therapeutics
Moderators
Albert B. Deisseroth, MD, PhD
Murali Ramachandra, PhD

Oral Abstract Session 247
Gene Regulation: Stem Cells
Moderators
Sonya J. Franklin, PhD
Casey C. Case, PhD

Evening Symposium 251
7:00 pm – 9:30 pm
NIH Funded Resources in Support of Gene Therapy
Chair
Joseph C. Glorioso, PhD
Speakers
Rosemarie Aurigemma, PhD
Allan Shipp
Richard A. Knazek, MD
Richard Lymn, PhD
Sonia Skarlatos, PhD

Corporate Symposium
7:00 pm – 10 pm
Zinc Finger DNA-Binding Proteins for Gene Regulation and Gene Correction: A Novel Class of Human Therapeutics
Supported by Sangamo BioSciences, Inc.

Zinc finger DNA binding proteins (ZFPs) can be engineered to create transcription factors that up- or down- regulate the expression of endogenous genes (ZFP TFs) and targeted nucleases (ZFNs) designed to make specific cuts in the genome to facilitate homologous recombination and gene repair. The goal of this symposium is to provide an overview of ZFPs, ZFP TFs, and ZFNs. Discussion will include their potential use as novel therapeutics in gene regulation, specifically for the treatment of ischemic cardiovascular disease and congestive heart failure, and also in targeted gene correction to treat X-linked SCID and Sickle cell anemia.

Chair
Sir Aaron Klug, OM, FRS

Confirmed Speakers
Sir Aaron Klug, OM, FRS - Why Engineered Zinc Finger DNA-Binding Proteins (ZFPs)?

Philip Gregory, DPhil - Specific Differential Technical Advantages of ZFPs for Therapeutic Applications

Frank Giordano, MD - ZFP TFs for the Treatment of Cardiovascular Disease

Matthew Porteus, MD, PhD - Targeted Gene Correction

Donald B. Kohn, MD - Therapeutic Applications of ZFP-Mediated Targeted Gene Correction